Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer

Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non‐small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as antibodies against PD‐1 and PD‐L1, in patients with lung cancer has increased our ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jun, Huang, Miao, Zhang, Li, Wu, Nan, Bai, Chun‐Xue, Chen, Liang‐An, Liang, Jun, Liu, Qian, Wang, Jie, Wu, Yi‐Long, Zhang, Feng‐Chun, Zhang, Shu‐Yang, Chen, Chun, Chen, Jun, Fang, Wen‐Tao, Gao, Shu‐Geng, Hu, Jian, Jiang, Tao, Li, Shan‐Qing, Li, He‐Cheng, Liao, Yong‐De, Liu, Yang, Liu, De‐Ruo, Liu, Hong‐Xu, Liu, Jian‐Yang, Liu, Lun‐Xu, Wang, Meng‐Zhao, Wang, Chang‐Li, Yang, Fan, Yang, Yue, Zhang, Lan‐Jun, Zhi, Xiu‐Yi, Zhong, Wen‐Zhao, Guan, Yu‐Zhou, Guo, Xiao‐Xiao, He, Chun‐Xia, Li, Shao‐Lei, Li, Yue, Liang, Nai‐Xin, Lu, Fang‐Liang, Lv, Chao, Lv, Wei, Si, Xiao‐Yan, Tan, Feng‐Wei, Wang, Han‐Ping, Wang, Jiang‐Shan, Yan, Shi, Yang, Hua‐Xia, Zhu, Hui‐Juan, Zhuang, Jun‐Ling, Zhuo, Ming‐Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Clinical Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088961/
https://www.ncbi.nlm.nih.gov/pubmed/33787090
http://dx.doi.org/10.1111/1759-7714.13942

Ejemplares similares

Ejemplares similares